Palard-Novello, Xavier
Visser, Denise
Tolboom, Nelleke
Smith, Charlotte L. C.
Zwezerijnen, Gerben
van de Giessen, Elsmarieke
den Hollander, Marijke E.
Barkhof, Frederik
Windhorst, Albert D.
van Berckel, Bart NM
Boellaard, Ronald
Yaqub, Maqsood
Article History
Received: 19 December 2023
Accepted: 27 February 2024
First Online: 13 March 2024
Declarations
:
: Patients were included in studies approved by the Medical Ethics Review Committee of the Amsterdam UMC (NL80924.029.22 for the TBPETCT001 study and NL77033.029.21 for the VECOSCO study).
: Informed consent was obtained from all individual participants included in the study.
: Siemens Healthineers provided e7 tools and contributed to the acquisition of the total body PET-CT system in the Amsterdam UMC Imaging Center. Competing interests: Frederik Barkhof is a steering committee or data safety monitoring board member for Biogen, Merck, ATRI/ACTC and Prothena, is a consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics, has research agreements with Merck, Biogen, GE Healthcare, Roche and is the co-founder and shareholder of Queen Square Analytics LTD. No other potential conflict of interest relevant to this article was reported.